The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and ...